On April 26, Taiji Group issued an announcement stating that recently, its holding subsidiary, Southwest Pharmaceutical Co.
(abbreviated as: Southwest Pharmaceutical), received a drug registration certificate for caffeine citrate injection issued by the National Medical Products Administration.
The indications are: for the treatment of primary apnea in premature newborns.
Caffeine citrate injection is a Class B drug in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Catalog (2020 Edition)".
As of the date of this announcement, after inquiring the database of the National Medical Products Administration, 4 domestic companies have production approval documents for this product, and Southwest Pharmaceutical is the fifth company to obtain a generic listing.
According to statistics from the "Menet" database, the total sales of the drug in Chinese urban public hospitals in 2019 were about 229.
66 million yuan, and the total sales in Chinese urban public hospitals in the first half of 2020 were about 113.
89 million yuan.
Up to now, the cumulative investment in research and development of this product is about 6.
944 million yuan (unaudited).